Nintedanib is a medication used in the trial to help slow down the progression of idiopathic pulmonary fibrosis (IPF). It works by blocking certain enzymes that contribute to the scarring of lung tissue, which can help improve lung function and breathing in patients with IPF.

Pirfenidone is another treatment option in the study for patients with idiopathic pulmonary fibrosis. It helps reduce lung scarring and inflammation, potentially slowing the disease’s progression and preserving lung function.

Investigational Product A is a new treatment being tested in the trial for its effectiveness in treating idiopathic pulmonary fibrosis. The goal is to determine if it can improve lung function and slow disease progression compared to existing treatments.

Investigational Product B is another new therapy under investigation in the study. Researchers are evaluating its safety and ability to improve lung function in patients with idiopathic pulmonary fibrosis, aiming to offer a new treatment option for this condition.

Idiopathic Pulmonary Fibrosis – Idiopathic pulmonary fibrosis is a chronic lung disease characterized by the thickening and scarring of lung tissue, leading to a progressive decline in lung function. The exact cause of this condition is unknown, which is why it is termed “idiopathic.” Over time, the scarring, or fibrosis, makes it increasingly difficult for the lungs to transfer oxygen into the bloodstream. Patients often experience symptoms such as persistent dry cough and shortness of breath, especially during physical activity. As the disease progresses, these symptoms can become more severe, impacting daily activities and quality of life. The progression of the disease varies among individuals, with some experiencing a rapid decline in lung function while others may have a slower progression.